ARK Genomic Revolution ETF
ARKG CBOE - exBATS
Companies within ARKG are focused on and are expected to substantially benefit from extending and enhancing the quality of human and other life by incorporating technological and scientific developments and advancements in genomics into their business with exposure to CRISPR, gene editing, therapeu...
Hover to inspectDrag to measure a move← → to step through days
- Fund size
- 538M as of Feb 2020
- Expense ratio
- 0.75% per year
- Dividend yield
- 0.00% Yearly
- Volatility · 1Y
- 45.8% High Risk
- Beta
- 1.59 vs the market
- 52-week range
- 24.8256.77
How ARKG has paid off
Price return over every period, and total return with dividends reinvested, set against price alone.
Return by period
Price · to Oct 12Total return vs price return
Price onlyOver 1 year, ARKG returned +63.4% with dividends reinvested — dividends added 0.0 pts to the price move.
How bumpy is the ride?
Return only means something next to the risk taken to earn it. Volatility, drawdowns and market sensitivity over 1 year.
Volatility
Annualized · 1YA typical year sees the price swing about ±46% around its trend.
Drawdown from peak
How far below its previous high the price has been Deepest fall −27.5% on Mar 30, 2026 — 67 days after the previous high
More than 5% below a high 73% of the time.
Market sensitivity
BetaA beta of 1.59 means ARKG has moved more than the market.
Trend & momentum
Where the price sits against its moving averages, and how stretched the recent move is.
Price vs moving averages
Uptrend- 12-day average51.51 −3.9%
- 26-day average50.63 −2.3%
- 50-day average48.18 +2.7%
- 200-day average38.51 +28.5%
The price is above 2 of 4 averages. The 50-day average is above the 200-day, a sign of a rising longer-term trend.
Relative strength (RSI)
NeutralRSI compares recent gains with recent losses on a 0–100 scale. Above 70 a move is often considered stretched, below 30 washed out.
Technical indicators describe past prices. They are not a forecast.
Inside the fund
Health Care · Research Advancement — tracking the Not Applicable.
- Assets under management538MUSD
- Expense ratio0.75%per year
- Holdings39
- Risk score6.0Medium
Launched October 2014. Fund data as of Feb 27, 2020.
Where ARKG shows up
Curated themes and indices that hold ARKG. Open one to see it in context, or test the whole theme in a portfolio.
Filings & reports
Regulatory filings, reports and announcements, newest first.
| Quarterly Webinar Q2 -2019 | Jul 11, 2019 | |
| Quarterly Webinar Q1-2019 | May 2, 2019 |
About ARK Genomic Revolution ETF
Companies within ARKG are focused on and are expected to substantially benefit from extending and enhancing the quality of human and other life by incorporating technological and scientific developments and advancements in genomics into their business with exposure to CRISPR, gene editing, therapeutics, agricultural biology and health care innovation
- Featured in 2 curated themes
- 39 holdings
- 2 documents on file
- Ticker
- ARKG
- Exchange
- CBOE - exBATS
- ISIN
- US00214Q3020
- CUSIP
- 00214Q 302
- Currency
- U.S. Dollar (USD)
- Country
- USA
- Sector
- Health Care
- Industry
- Research Advancement
- Benchmark
- Not Applicable
All key statistics
Details
Shareas of Oct 12, 2026
Dataas of Feb 27, 2020
Put ARKG to the test
See how it would change the return and the risk of a portfolio, with virtual money, before a single real dollar moves.
Data for information only, not investment advice. Past performance does not guarantee future results.